Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 2902-2911

  Chhabra, D ^a   Alvarado, A ^b   Dalal, P ^b   Leventhal, J ^b   Wang, C ^c   Sustento Reodica, N ^b,d   Najafian, N ^e   Skaro, A ^b   Levitsky, J ^b   Mas, V ^f   Gallon, L ^b  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Graft function; graft survival; kidney transplantation; prednisone free; sirolimus; tacrolimus

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BK VIRUS INFECTION; CELLULITIS; CONTROLLED STUDY; CYCLOSPORIASIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HERPES SIMPLEX; HISTOPLASMOSIS; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEOPLASM; NEPHROTOXICITY; PERIPHERAL EDEMA; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RENAL GRAFT DYSFUNCTION; RHINOPHARYNGITIS; SURVIVAL; TREATMENT OUTCOME; URINARY TRACT INFECTION;

GRAFT FUNCTION; GRAFT SURVIVAL; KIDNEY TRANSPLANTATION; PREDNISONE-FREE; SIROLIMUS; TACROLIMUS;

ADULT; ALLOGRAFTS; ANTI-INFLAMMATORY AGENTS; CALCINEURIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84886800500     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12437     Document Type: Article

References (58)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
2. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart-transplant patients. Kidney Int 1991; 40: 243-250.
3. Davies DR, Bittmann I, Pardo J., Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000; 69: SS11-SS13.
4. Bennett WM., Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34: 515-519.
5. Pascual M, Swinford RD, Ingelfinger JR, Williams WW, Cosimi AB, Tolkoff-Rubin N., Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998; 19: 514-519.
6. Remuzzi G, Perico N., Cyclosporine-induced renal dysfunction in experimental-animals and humans. Kidney Int 1995; 48: S70-S74.
7. Solez K, Vincenti F, Filo RS., Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736-1740.
8. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
9. Kaplan B, Schold JD, Meier-Kriesche HU., Long-term graft survival with neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980-2984.
10. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707.
11. Chapman JR., Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693-697.
12. Matas AJ., Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 2011; 11: 687-692.
13. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
14. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
15. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324-330.
16. Knight RJ, Kahan BD., The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity ? Kidney Int 2006; 70: 994-999.
17. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
18. Dean PG, Grande JP, Sethi S, et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212-1215.
19. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892.
20. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
21. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
22. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
23. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
24. Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB., Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1: 1029-1038.
25. Amundsen B, Gallon LG, Kaufman D, Walker J, Leventhal JR, editors. Steroid avoidance and delayed introduction of tacrolimus using alemtuzumab induction in kidney transplantation: Five year follow-up. Am J Transplant 2007; 7 (Suppl 2, Abstract #A237): 208.
26. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-474.
27. Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826-1835.
28. Schulz K, Altman D, Moher D., CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Br Med J 2010; 340: 698-702.
29. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
30. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
31. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785.
32. Hamdy AF, Bakr MA, Ghoneim MA., Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008; 19: 1225-1232.
33. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77: 1228-1235.
34. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
35. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
36. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.
37. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175-183.
38. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744-2753.
39. Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012; 12: 1528-1540.
40. Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation. Transpl Int 2012; 25: 416-423.
41. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665-1675.
42. Heilman RL, Younan K, Wadei HM, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 2011; 92: 767-773.
43. Holdaas H, Rostaing L, Serõn D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.
44. Ojo AO., Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611.
45. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA., Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153-1162.
46. Aakhus S, Dahl K, Widerøe TE., Cardiovascular disease in stable renal transplant patients in Norway: Morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596-604.
47. Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008; 8: 1871-1877.
48. Anavekar NS, Gans DJ, Berl T, et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria. Kidney Int Suppl 2004; Nov: S50-S55.
49. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS., Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997.
50. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438-444.
51. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854-861.
52. Diekmann F, Gutiérrez-Dalmau A, Lõpez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 2007; 22: 2316-2321.
53. Franco AF, Martini D, Abensur H, Noronha IL., Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007; 39: 449-452.
54. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C., The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499.
55. Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M., The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant 2013; 13: 442-449.
56. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804-2812.
57. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
58. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192-1198.